October 31, 2022 ELITA 30th Anniversary Meeting & ELITA-EF CLIF Monothematic Conference about ACLF, Alcohol and Liver Transplant On the occasion of the 30th Anniversary of the European Liver and Intestine Transplant Association (ELITA), we join efforts with this section of the European Society for Organ Transplantation (ESOT), to bring together experts in acute-on-chronic liver failure (ACLF) and liver transplantation to discuss current practices and the future of the field in Europe.

Target group: Liver and transplant surgeons, hepatologists, intensive care specialist, transplant anaesthesiologists, transplant fellows.

The purpose of the Monothematic Conference is to provide up-to-date scientific evidence on the role of liver transplantation in patients with acute-on-chronic liver failure (ACLF) or in active drinkers who are in urgent need of a liver transplant. More specifically, the two morning sessions will be dedicated to the diagnosis of ACLF and to the crucial issue of access to liver transplantation for patients with severe ACLF across Europe. The afternoon sessions will focus on the current treatment of alcoholic hepatitis and the place of liver transplantation in active drinkers. For both topics there will be round table discussion based on clinical cases.

Register on the ELITA website >


The European Liver and Intestine Transplant Association (ELITA), previously known as the European Liver Transplant Association (ELTA), is a section of ESOT. Its membership represents the expertise on liver and intestinal transplantation in Europe.

To provide a forum for those working in the field of liver and intestinal transplantation to exchange scientific information and views related primarily to providing the best service for patients in Europe requiring liver transplantation. Thus science, training, organ sharing and distribution, co-operative research projects, especially of clinical nature and the European Liver Transplant Registry would be of concern.

The relationship with national and European government agencies and with the organ exchange organisations would also be the business of the ELITA, which would be the official representative body of liver and intestinal transplantation in Europe.


The European Foundation for the Study of Chronic Liver Failure (EF CLIF) is a private non-profit organization connecting biomedical researchers and healthcare professionals with each other, with patients and patient associations, and with society. The fundamental purpose of EF CLIF, reflected in its founding Statements of 2015, is to advance knowledge and promote research and education in liver disease to improve the prognosis of patients living with chronic liver disease.

The Foundation has made pioneering efforts in conducting a series of large, international prospective studies that have been instrumental in reclassifying the trajectory of patients with chronic liver failure and led to the clinical, prognostic and pathophysiological definition of the syndrome referred to as “acute-on-chronic liver failure” characterized by acute decompensation of cirrhosis, severe systemic inflammation, organ failures, and high short-term mortality. We are inspiring best clinical practices for the management of patients with chronic liver failure and promoting a more sustainable and equitable healthcare system.

Within the Foundation, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL- CLIF Consortium, a network of 117 tertiary care and university hospitals in 28 European countries. The Grifols Chair promotes translational studies in centers across Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers in 8 countries. Over the last five years, the Foundation has successfully expanded its geographical scope providing the context to support transcontinental collaborative research projects. The Global Projects chapter provides the framework to promote research in cirrhosis across the world with the aim to help to build consensus and ensure health equity worldwide.